33 Atopic Dermatitis Clinical Trials in Sacramento, CA (2026)

Q: How do I join a clinical trial in Sacramento?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you.

Recruiting Atopic Dermatitis Studies in Sacramento

NCT02693535Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

Sacramento, CAPHASE24,200 participantsAmerican Society of Clinical Oncology

View Study Details

NCT04194138Recruiting

Complex Adult Deformity Surgery (CADS)

Evaluate surgical treatment outcomes and identify best practice guidelines for complex adult spinal deformity (ASD) patients, including radiographic and clinical outcomes, surgical and postoperative c...

Sacramento, CA1,500 participantsInternational Spine Study Group Foundation

View Study Details

NCT05614739Recruiting

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435...

Sacramento, CAPHASE1677 participantsEli Lilly and Company

View Study Details

NCT06461897Recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial parti...

Sacramento, CAPHASE3675 participantsAbbVie

View Study Details

NCT06788990Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficeraf...

Sacramento, CAPHASE2650 participantsBicara Therapeutics

View Study Details

NCT07711418Recruiting

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe...

Sacramento, CAPHASE3510 participantsNektar Therapeutics

View Study Details

NCT07276399Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or ...

Sacramento, CAPHASE3500 participantsJanssen Research & Development, LLC

View Study Details

NCT04429542Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergis...

Sacramento, CAPHASE1473 participantsBicara Therapeutics

View Study Details

NCT07106762Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy...

Sacramento, CAPHASE2470 participantsBristol-Myers Squibb

View Study Details

NCT06264180Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage III...

Sacramento, CAPHASE3400 participantsReplimune Inc.

View Study Details

NCT05592626Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with ad...

Sacramento, CAPHASE1366 participantsMarengo Therapeutics, Inc.

View Study Details

NCT05684965Recruiting

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

Sacramento, CAPHASE1358 participantsXilio Development, Inc.

View Study Details

NCT06439277Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity ...

Sacramento, CAPHASE3300 participantsEli Lilly and Company

View Study Details

NCT07599813Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study....

Sacramento, CAPHASE2280 participantsApollo Therapeutics Ltd

View Study Details

NCT06947993Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD)....

Sacramento, CAPHASE2224 participantsNovartis Pharmaceuticals

View Study Details

NCT06521554Recruiting

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in parti...

Sacramento, CAPHASE1200 participantsNuvalent Inc.

View Study Details

NCT06311682Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat ...

Sacramento, CAPHASE3195 participantsLEO Pharma

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Sacramento, CAPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT07387367Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-dr...

Sacramento, CAPHASE3180 participantsSymBio Pharmaceuticals

View Study Details

NCT06366464Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The ...

Sacramento, CAPHASE3134 participantsHarmony Biosciences Management, Inc.

View Study Details

NCT06397911Recruiting

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic de...

Sacramento, CAPHASE2114 participantsOneness Biotech Co., Ltd.

View Study Details

NCT03952299Recruiting

Oxybutynin for Post-surgical Bladder Pain and Urgency

Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency....

Sacramento, CAPHASE3100 participantsUniversity of California, Davis

View Study Details

NCT06778863Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation....

Sacramento, CAPHASE190 participantsClasp Therapeutics, Inc.

View Study Details

NCT06352359Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose ...

Sacramento, CAPHASE172 participantsOncoC4, Inc.

View Study Details

NCT06436157Recruiting

A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention

Genetic factors are a significant determinant of the likelihood of developing various types of cancers. Identification of germline risk can have important implications for both patients and their fami...

Sacramento, CANA60 participantsUniversity of California, Davis

View Study Details

NCT06524635Recruiting

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of th...

Sacramento, CAPHASE260 participantsAbbVie

View Study Details

NCT07189195Recruiting

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant p...

Sacramento, CAPHASE152 participantsUniversity of California, Davis

View Study Details

NCT03221244Recruiting

Virtual Reality Attention Management

Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to dist...

Sacramento, CANA50 participantsUniversity of California, Davis

View Study Details

NCT06800963Recruiting

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not...

Sacramento, CAPHASE140 participantsImmunityBio, Inc.

View Study Details

NCT06041048Recruiting

Investigation of Locus Coeruleus Function in Sustained Attention

The norepinephrine-producing locus coeruleus (LC) is thought to be central to a wide array of cognitive functions, like attention and goal pursuit, and has been implicated in dysfunctions including at...

Sacramento, CAPHASE440 participantsUniversity of California, Davis

View Study Details

NCT06860594Recruiting

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a peri...

Sacramento, CAPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

NCT06722508Recruiting

Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients

This study examines the acceptability, feasibility, and safety in developing a prehabilitation program for head and neck cancer patients. The purpose of this research is to access the safety and accep...

Sacramento, CANA20 participantsUniversity of California, Davis

View Study Details

NCT06173349Recruiting

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasive bladder cancer that has come back afte...

Sacramento, CAPHASE112 participantsUniversity of California, Davis

View Study Details

About Atopic Dermatitis Clinical Trials in Sacramento

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 33 atopic dermatitis clinical trials recruiting participants in Sacramento, CA. These studies are seeking a combined 13,218 participants. Research is being sponsored by American Society of Clinical Oncology, International Spine Study Group Foundation, Eli Lilly and Company and 21 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Sacramento — FAQ

Are there atopic dermatitis clinical trials in Sacramento?

Yes, there are 33 atopic dermatitis clinical trials currently recruiting in Sacramento, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Sacramento?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.

Are clinical trials in Sacramento free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 33 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 15, 2026 from ClinicalTrials.gov